LAMA2 and muscular dystrophy: However, many obstacles to SC transplantation still exist, such as SCs’ limited number, delivery methods, cell source (auto or allogeneic) as reviewed by Almeida et al. (2016), and need to be addressed before considering SC therapy for LAMA2-CMD patients or other muscular dystrophies with more widespread muscle involvement.